Background
==========

The endothelium, which lines the inner surface of all blood vessels, participates in several normal physiological functions including control of vasomotor tone, the maintenance of blood fluidity, regulation of permeability, formation of new blood vessels, and trafficking of cells \[[@B1]\]. The endothelium also plays an important role in several human diseases. In the setting of inflammation several genes become activated within the endothelium to facilitate the recruitment, attachment, and transmigration of inflammatory cells. Over time, however, in chronic inflammatory diseases EC responses become impaired, leading to EC dysfunction.

As a cell type, ECs exhibit tremendous heterogeneity \[[@B2]\]. For example, there are significant differences in EC structure and function based on the size and type of blood vessel, from larger arteries or veins, to medium sized arterioles or venules, down to capillary ECs. There is also significant heterogeneity at the level of a particular tissue or organ. For example, in the brain, the endothelium plays a particularly important protective role as part of the blood brain barrier with ECs that are closely attached to one another forming a tight barrier that is impermeable to the passage of even small solutes or ions. In contrast, in the liver, the sinusoidal ECs are fenestrated so that small to moderate size transcellular pores promote the uptake of large lipid containing particles from the blood \[[@B3],[@B4]\].

The endothelium is known to play an important role in several human diseases including atherosclerosis, diabetes mellitus, and sepsis. The overall goal of the current study was to use primary and publicly available microarray data from human ECs, non ECs, and tissues, to identify genes that exhibit an EC-restricted pattern, define their distribution in different tissues, and determine whether changes in the expression of any of the genes are linked to particular diseases. Our study, has for the first time, identified and ranked a significant number of genes that exhibit an EC-restricted expression pattern. Among these genes, several interesting patterns of expression emerge. Whereas many of the genes are expressed in all ECs, some are restricted to microvascular ECs. The vast majority of EC-restricted genes are expressed in multiple tissues. The EC-restricted genes were found to be associated with a number of different cellular functions including vasculature development, cell differentiation, and angiogenesis. Analysis of the regulatory regions of the EC-restricted genes demonstrated enrichment of binding sites for a selected number of transcription factors and microRNAs.

Methods
=======

Cell culture
------------

HUVEC (human umbilical vein EC cell; Lonza), HAEC (human aortic EC cells), HCAEC (human coronary artery EC cells), HPAEC (human pulmonary artery EC cells), and HMVEC (human microvascular (dermal) EC cell; kindly provided by Dr. William Aird) were grown in EBM-2 (EC Cell Basal Medium-2) supplemented with EGM SingleQuots (Lonza). HASMC (human aortic smooth muscle cell) were grown in SmBM Basal Medium supplemented with SmGM-2 SingleQuot (Lonza). For the isolation of the T and B cells, discarded leukocytes from platelet donations by healthy human donors were used in this study. Samples were obtained from subjects after informed consent was obtained using an institutionally approved protocol (IRB protocol 2005-P-001364/2). Red blood cells were removed using Ficoll-Paque PLUS according to manufacturer\'s protocol. (GE-Healthcare. Uppsala Sweden). Donor Peripheral Blood Mononuclear Cells (PBMC) were stained with pan T-cell specific CD3-PE and pan B-cell specific CD20-FITC antibodies. Fluorescently labeled cells were sorted using a high speed cell sorter. (FACS Aria. BD biosciences San Jose. California).

RNA isolation
-------------

Total RNA was isolated using the RNAeasy kit (QIAGEN) following the manufacturer\'s instructions.

Microarray Analysis
-------------------

Transcriptional profiling of endothelial and non-EC cells was performed using the Affymetrix oligonucleotide microarray HT U133 plate with 24 chips according to a standard Affymetrix protocol for cDNA synthesis, *in vitro*transcription, production of biotin-labeled cRNA, hybridization of cRNA with HT Plate A and B, and scanning of image output files \[[@B5]\]. The quality of hybridized chips was assessed using Affymetrix guidelines on the basis of average background, scaling factor, number of genes called present, 3\' to 5\' ratios for beta-actin and GAPDH and values for spike-in control transcripts \[[@B6]\]. We also checked for reproducibility of the samples by using chip to chip correlation and signal-to-noise ratio (SNR) methods for replicate arrays. All the high quality arrays were included for low and high level bioinformatics analysis. Primary gene expression data are publicly available at GEO <http://www.ncbi.nlm.nih.gov/geo/> in GSE21212.

Statistical Analysis
--------------------

To obtain the signal values, high quality chips were further analyzed by dChip, as it is more robust than MAS5.0 and RMA in signal calculation. The raw probe level data was normalized using smoothing-spline invariant set method. The signal value for each transcript was summarized using PM-only based signal modeling algorithm described in dChip. The PM only based modeling based algorithm yields less number of false positives as compared to the PM-MM model. In this way, the signal value corresponds to the absolute level of expression of a transcript\[[@B7]\]. These normalized and modeled signal values for each transcript were used for further high level bioinformatics analysis. During the calculation of model based expression signal values, array and probe outliers are interrogated and image spikes are treated as signal outliers.

When comparing two groups of samples to identify genes enriched in a given phenotype, if the 90% lower confidence bound (LCB) of the fold change (FC) between the two groups was above 3 and median false discovery rate is \<2%, the corresponding gene was considered to be differentially expressed \[[@B8]\]. LCB is a stringent estimate of FC and has been shown to be the better ranking statistic \[[@B9]\]. It has been suggested that a criterion of selecting genes that have an LCB above 2.0 most likely corresponds to genes with an \"actual\" fold change of at least 3 in gene expression \[[@B8],[@B10]\].

Identification of EC-restricted genes
-------------------------------------

The list of differentially expressed genes obtained from the primary analysis (previous section) was further analyzed through a series of steps to obtain EC-restricted genes. This analysis was performed using the following three steps, i); determination of the enrichment score, ii); performing an outlier analysis, and iii); ranking the genes according to EC specificity.

i) Enrichment Score \[ECS\]
---------------------------

The enrichment analysis was performed to determine the probability that genes are specifically over expressed in ECs as compared to other primary non-ECs. For this analysis we used the public REFEXA database <http://www.lsbm.org/site_e/database/index.html>. The REFEXA database consists of gene expression data from a series of primary cells, cancer cell lines, and tissues. The MAS5 normalized data was manually obtained from the database for all the transcripts that were identified as highly expressed in ECs compared to non-ECs in the primary analysis. The enrichment score of each gene was determined by calculating the relative expression in the ECs compared to non-ECs. Each transcript was assigned a present/absent call in every primary cell on the basis of expression value. The transcript is called present (P) in a primary non-endothelial cell if it was expressed \>50% of the expression level in the primary ECs, otherwise it was called absent (A). The EC score (ECS) is obtained using the following equation:

where ECS~j~is the enrichment score for a transcript j, A~i~and P~i~are the present and absent calls for the transcript in different normal primary cells (n).

ii) Outlier Analysis
--------------------

The outlier analysis was performed on the list of genes obtained after step i) for the selection of genes with restricted EC expression. The outlier analysis was performed by means and standard deviation of the expression values using publicly available microarray data. If the expression of a given transcript in a sample falls 2 standard deviations outside of the mean expression in the distribution obtained using all samples, the particular sample is considered as an outlier. If the cluster of the outliers consists only of ECs, the genes were considered as good candidates for being EC-restricted. On the contrary, if the cluster of the outliers consists of ECs and non-ECs, these genes were considered to have less specificity for ECs and were filtered out from the final analysis.

iii) Ranking of EC-restricted genes
-----------------------------------

After the outlier and enrichment analysis, all the identified EC-restricted genes were ranked on the basis of average fold change of a gene in ECs as compared to non ECs (REF_FOLD) in publicly available datasets (REFEXA) and Fold change between ECs and non-ECs from our primary experiment (FC) \[EQ 2\]. The genes with high REF_FOLD and high FC are considered to be more EC-restricted and assigned a higher rank.

where REF_FOLD = (Expression in ECs in public set/Expression in Non-EC) and FC = (Expression in ECs in primary set/Expression in Non-EC).

To further reduce the false positive rate, we have selected the top 60% of the transcripts with greater than 3 fold expression in ECs compared to non-ECs as good candidates for endothelial restriction.

Pathways, Gene ontology and Disease set enrichment analysis of EC-restricted genes
----------------------------------------------------------------------------------

The functional analysis of the EC-restricted genes was performed in terms of canonical pathways, disease sets and gene ontology (GO) categories. The canonical pathways and disease set enrichment analysis was performed using the MetaCore tool of GeneGo package <http://www.genego.com/>. It consists of manually curated information about gene regulation, protein interactions, and metabolic and signaling pathways. The overrepresented canonical pathways and disease biomarker sets were ranked on the basis of P values obtained using the Simes procedure accounting for multiple hypothesis testing representing the probability of mapping arising by chance, based on the number of EC-restricted genes identified in a particular canonical pathway or disease compared to the total number of genes in the GO category/Disease set. The Go categories/Disease set with a False Discovery Rate (FDR) corrected P value \<0.05 were considered significant.

The Database for Annotation, Visualization and Integrated Discovery (DAVID) was used to identify over-represented gene ontology categories form the endothelial restricted genes \[[@B11]\]. DAVID is an online implementation of the EASE software that produces the list of overrepresented categories using jackknife iterative resampling of the Fisher exact probabilities. A score was assigned to each category by using \"-log\" of EASE score to show the significantly enriched gene ontology categories. The related gene ontology categories were merged into a cluster using the functional clustering module of DAVID. Higher enrichment scores for particular genes reflect increasing confidence in their over-representation.

Analysis of transcription factor binding sites
----------------------------------------------

Recent improvements in bioinformatics methods for the analysis of sequences regulating transcription have made it possible to elucidate potential factors involved in regulating key regulatory networks underlying a transcriptional response. We divided the EC specific genes into two sets on the basis of K Mean clustering for promoter analysis i) high expression in all ECs ii) and high expression in HMVEC. The promoter analysis was performed separately on these two sets using the online tool ExPlain <http://explain.biobase-international.com/cgi-bin/biobase/ExPlain_2.4.2/> for detection of over-represented transcription factor binding sites. ExPlain uses the MatchTM, a weight matrix-based tool for searching putative transcription factor binding sites \[[@B12],[@B13]\].

For the analysis, we selected regions from 2000 bp upstream to 100 bp downstream of the transcription start site of each gene (Yes set). The enrichment was obtained against a random set of promoters obtained from human housekeeping genes (No set). The entire vertebrate non-redundant set of transcription factors matrix from transfac database was used for scanning potential binding sites \[[@B14]\]. The matrices that did not differ much in density between the positive and negative set were removed from the results. A significant over-representation of a transcription factor binding site in a target set as compared to the background set was determined using a 1-tailed Fisher exact probability test *\[P value \< 0.01,FC (yes_set/no_set) \> 1.2)*. After completion of the enrichment analysis, the transcription factor binding sites for each set were compared with each other, in order to identify TF binding sites that were common and distinct among the different types of ECs (e.g. all, microvascular).

MicroRNA target analysis
------------------------

Another potential mechanism of regulating EC specific genes could be through miRNA, a class of small non-coding RNAs, that regulate gene expression primarily through post-transcriptional repression by promoting mRNA degradation in a sequence-specific manner \[[@B15]\]. We were interested in identifying whether miRNA binding sites are enriched in EC-restricted genes. Computational analysis of the miRNA targets sites was performed using **C**omposite **R**egulatory **S**ignature **D**atabase (**CRSD**) <http://140.120.213.10:8080/crsd/main/home.jsp>, a comprehensive server for composite regulatory signature discovery. CRSD has a package for prediction of miRNA binding sites by searching the UTRs for segments of perfect Watson-Crick in the 3\'UTR of the target gene set \[[@B16]\].The miRNA binding sites for each of the micro RNA are calculated in the EC-restricted set and the background set (54,576 genes from human unigenes). The enrichment of each miRNA binding site is calculated on the basis of its abundance in the EC-restricted set and the background set. The significance of enrichment is expressed as a P value (smaller the P value more significant is the enrichment).

Tissue specificity of EC specific Gene
--------------------------------------

In order to determine the normal tissue distribution of the EC specific genes, we obtained the normalized expression level from the Stanford Source database \[[@B17]\]. Source database presents the relative expression level of a gene in different tissues that is normalized for the number of samples from each tissue included in UniGene. The gene expression information for the different transcripts was obtained from dbEST expression profile.

In addition to relative gene expression information from the Source database, we have also manually curated the protein expression information about the endothelial specific genes from the Human Protein Atlas database. The Human Protein Atlas is a comprehensive database that provides the protein expression profiles for a large number of human proteins, presented as immunohistological images from most human tissues \[[@B18],[@B19]\]. It contains antibody-based protein expression and localization profiles of \>4,000 proteins in 48 normal human tissues and 20 different cancers \[[@B20]\]. The expression level of each protein is presented in a four color scale system that takes into consideration the intensity of the protein expression and quantity of positive images tested for each protein. It is a very useful tool to extract the relative expression level of proteins in different tissues.

Quantitative real-time PCR
--------------------------

Total RNA was isolated using the RNAeasy kit (QIAGEN, Valencia, CA). Single stranded cDNA was synthesized from total RNA using High Capacity RNA-to-DNA Kit (Applied Biosystems). SYBR Green I-based real-time PCR was carried out on an Opticon Monitor. The sequences of the primers used in this study are listed in Additional File [1](#S1){ref-type="supplementary-material"}. For normalization of each sample, human specific TATA-binding protein (TBP) primers were used to measure the amount of TBP cDNA.

Results
=======

Identification of EC-restricted genes
-------------------------------------

In an effort to identify genes that exhibit an EC-restricted pattern total RNA was isolated from primary cultured ECs (including HUVEC, HPAEC, HAEC, HMVEC, and HCAEC) and non-ECs (HASMC, B cells, T cells). Gene expression profiling was performed using a high throughput platform, HT U133 plate, that measures more than 43,000 well-characterized genes and UniGene clusters. The expression profiling was performed in duplicate. All the array data was determined to be of high quality as assessed by the scaling factor, average background, percent present calls, and 3\'/5\'RNA ratio. After normalization and preprocessing of the data, we generated a list of genes that are significantly differentially expressed between different ECs and non-ECs. The heterogeneity in the transcription profile of the EC was identified using unsupervised clustering, reflecting the global similarities between the samples \[Figure [1A](#F1){ref-type="fig"}\]. Unsupervised clustering demonstrated the highest similarity within the biological replicates and the least similarity between ECs and non-ECs. The cladogram produced by unsupervised clustering depicted that venous and pulmonary arterial ECs are much closer in expression profile as compared to microvascular cells.

![**Overall approach for extraction of endothelial restricted genes**. A) Unsupervised Pearson Correlation based cluster of different EC and non-EC arrays after normalizing the data. ECs (HMVEC, HUVEC, HPVEC, HAEC, and HCEAC) form separate clusters from non-ECs (HSAMC, B Cells, T Cells). In most of cases biological replicates of each cell type have better correlation with each other than with other cell types. B) Venn diagram indicating overlap between microvascular, arterial and venous endothelial differentially expressed genes obtained from the primary analysis C) Schematic representation of the approach for identifying the genes with EC-restricted expression (EC-restricted) D) Venn diagram depicting the overlap between microvascular, arterial and venous endothelial restricted transcripts.](1471-2164-11-342-1){#F1}

Comparing groups, we found 1,713 transcripts that are differentially expressed in HMVEC compared to non-ECs (LCB \> 3 and FDR \< 2%). Similarly for HUVEC and HPVEC, 1,534 and 1,539 transcripts were respectively differentially expressed compared to non-ECs. For the arterial EC cells, 1,239 HCAEC and 1,316 HAEC transcripts were determined to be differentially expressed in these cells compared to non-ECs. Comparison of the differentially expressed transcripts in microvascular (HMVEC), venous (HUVEC, HPVEC) and arterial (HAEC, and HCAEC) cells using Venn diagrams revealed that approximately half of the transcripts are differentially expressed in all three EC types. However we also observed that each EC type possessed a unique expression signature; the differential expression of transcripts was limited to one type of EC \[Figure [1B](#F1){ref-type="fig"}\].

The total number of transcripts that are significantly different in at least one of the EC types compared to non-ECs consists of 2553, representing 1617 genes. To further refine our initial list of EC-restricted genes, we evaluated the expression of these genes using the data from REFEXA <http://www.lsbm.org/site_e/database/index.html> to identify EC-restricted genes. To calculate an enrichment score for each gene, expression values were manually obtained for each transcript using the REFEXA database <http://www.lsbm.org/site_e/database/index.html>. This database has MAS5 normalized gene expression data for several primary cells, including ECs, cancer cell lines, and normal tissues. For analysis we only used the expression data for 30 primary cells and excluded all cancer cell lines. The enrichment and outlier analysis identified 289 outlier transcripts with an enrichment score of 1 (see methods for details). To further reduce the number of false positive results, the top 60% (168 transcripts) of transcripts with an average of greater than or equal to 3 fold overexpression in EC cells as compared to non-EC cells were considered EC-restricted. The expression value of these 168 transcripts was manually checked and transcripts with reduced specificity were removed. After manual inspection of relative expression profiles of each transcript, we selected 152 transcripts that correspond to 109 valid genes exhibiting an EC-restricted pattern (Table [1](#T1){ref-type="table"}). The 152 transcripts with varying EC specificity are ranked on the basis of fold change in the primary set and fold change from the external datasets (e.g. REFEXA). The Rank score is a significance level with larger rank scores indicating increasing confidence in endothelial restriction. The overall schema of curating endothelial specific genes is shown in Figure [1C](#F1){ref-type="fig"}. Many genes that are known to be EC-restricted, including angiopoietin-2, von Willebrand\'s factor (vWF), VE-cadherin (CD144) are at the top of the list (Table [1](#T1){ref-type="table"}). Comparison of the EC-restricted transcripts in microvascular (HMVEC), venous (HUVEC, HPVEC) and arterial (HAEC, and HCAEC) cells using Venn diagrams revealed that most of the transcripts are differentially expressed in all three EC cell types. Only a small fraction of transcripts are uniquely differentially expressed in microvascular ECs \[Figure [1D](#F1){ref-type="fig"}\]. A colorogram demonstrating the expression pattern for each of the EC-restricted genes is shown in Figure [2](#F2){ref-type="fig"}. The colorogram consists of a range of patterns from transcripts highly expressed in all EC types (Pattern IV) to transcripts that are highly expressed in particular EC types (Pattern I). ANGPT2, TBX1, FLT4 are examples of genes that are highly expressed in the HMVEC cells. The expression patterns of EC-restricted genes were further confirmed using the REFEXA dataset \[Figure [3](#F3){ref-type="fig"}\]. To further validate the microarrays results, we used PCR to quantitate the expression levels of 12 randomly selected EC-restricted genes in primary ECs and non-ECs. A very similar EC-restricted expression pattern was observed for all 12 genes \[Figure [4](#F4){ref-type="fig"}\]. Although the relative fold enrichment of some of the EC-restricted genes was somewhat lower than initially identified by microarray analysis, the expression in non-ECs remained quite low or absent in comparison to ECs.

###### 

List of the endothelial restricted genes with detailed annotation and rank score

  Probe          Gene Symbol   UGCluster   FC       REFEXA_FC     Rank
  -------------- ------------- ----------- -------- ------------- -------------
  205612_at      MMRN1         Hs.268107   172.65   64.625        11157.50625
  204482_at      CLDN5         Hs.505337   124.75   47.5625       5933.421875
  202112_at      VWF           Hs.440848   61.15    78.05172414   4772.862931
  206464_at      BMX           Hs.495731   55.28    80.46153846   4447.913846
  205572_at      ANGPT2        Hs.583870   69.88    20.21875      1412.88625
  204904_at      GJA4          Hs.296310   37.23    34.5          1284.435
  204677_at      CDH5          Hs.76206    79.89    13.96610169   1115.751864
  204468_s\_at   TIE1          Hs.78824    78       14.19626168   1107.308411
  226028_at      ROBO4         Hs.524121   34.97    27.89130435   975.358913
  227779_at      ECSCR         Hs.483538   53.73    12.03448276   646.6127586
  222856_at      APLN          Hs.303084   76.9     8.106666667   623.4026667
  207526_s\_at   IL1RL1        Hs.66       64.53    9.56846473    617.453029
  204134_at      PDE2A         Hs.503163   43.51    13.72368421   597.1175
  214319_at      FRY           Hs.507669   38.96    15.2962963    595.9437037
  219059_s\_at   LYVE1         Hs.655332   88.96    6.384615385   567.9753846
  201785_at      RNASE1        Hs.78224    28.82    18.38461538   529.8446154
  236262_at      MMRN2         Hs.524479   28.44    18.28571429   520.0457143
  204818_at      HSD17B2       Hs.162795   133.64   3.846938776   514.104898
  220637_at      FAM124B       Hs.147585   17.93    23.09090909   414.02
  229902_at      FLT4          Hs.646917   19.45    20.94594595   407.3986486
  205392_s\_at   CCL14         Hs.714858   45.05    8.48          382.024
  223567_at      SEMA6B        Hs.465642   17.28    21.82608696   377.1547826
  211273_s\_at   TBX1          Hs.173984   35.43    10.18181818   360.7418182
  213715_s\_at   KANK3         Hs.322473   34.78    10.23076923   355.8261538
  222885_at      EMCN          Hs.152913   36.24    8.930555556   323.6433333
  206331_at      CALCRL        Hs.470882   44.19    7             309.33
  225369_at      ESAM          Hs.173840   14.83    20.10714286   298.1889286
  219837_s\_at   CYTL1         Hs.13872    47.07    5.946969697   279.9238636
  241926_s\_at   ERG           Hs.473819   79.8     3.44          274.512
  238488_at      LRRC70        Hs.482269   12.1     21            254.1
  203934_at      KDR           Hs.479756   40.75    6.224137931   253.6336207
  227923_at      SHANK3        Hs.149035   15.6     12.96296296   202.2222222
  225817_at      CGNL1         Hs.148989   27.25    7.260869565   197.8586957
  229002_at      FAM69B        Hs.495480   26.39    7.414634146   195.6721951
  228489_at      TM4SF18       Hs.22026    53.73    3.328         178.81344
  210082_at      ABCA4         Hs.416707   16.65    9.857142857   164.1214286
  235334_at      ST6GALNAC3    Hs.337040   24.36    6.659090909   162.2154545
  229309_at      ADRB1         Hs.99913    19.91    7.891891892   157.1275676
  235044_at      CYYR1         Hs.37445    23.53    5.6           131.768
  205569_at      LAMP3         Hs.518448   14.72    8.56          126.0032
  229233_at      NRG3          Hs.125119   19.5     6.285714286   122.5714286
  235050_at      SLC2A12       Hs.486508   17.4     6.363636364   110.7272727
  220027_s\_at   RASIP1        Hs.233955   16.99    6.03125       102.4709375
  204683_at      ICAM2         Hs.431460   9.09     11.23245614   102.1030263
  220300_at      RGS3          Hs.494875   29.92    3.411764706   102.08
  206283_s\_at   TAL1          Hs.705618   24.65    4.097222222   100.9965278
  227307_at      TSPAN18       Hs.385634   7.32     13.53333333   99.064
  206210_s\_at   CETP          Hs.89538    7.91     12.33333333   97.55666667
  228601_at      LOC401022     Hs.98661    12.94    7.36          95.2384
  218825_at      EGFL7         Hs.91481    13.85    6.789473684   94.03421053
  211518_s\_at   BMP4          Hs.68879    28.88    3.243243243   93.66486486
  229726_at      GRAP          Hs.567416   9.1      10.14285714   92.3
  229376_at      PROX1         Hs.585369   26.82    3.338461538   89.53753846
  204368_at      SLCO2A1       Hs.518270   17.02    5.051724138   85.98034483
  230132_at      ATP5SL        Hs.351099   22.49    3.585106383   80.62904255
  209543_s\_at   CD34          Hs.374990   17.19    4.68115942    80.46913043
  228311_at      BCL6B         Hs.22575    12.6     6.333333333   79.8
  219568_x\_at   SOX18         Hs.8619     3.72     21.42857143   79.71428571
  218736_s\_at   PALMD         Hs.483993   17.5     4.270072993   74.72627737
  204681_s\_at   RAPGEF5       Hs.174768   22.02    3.351851852   73.80777778
  239665_at      LOC441179     Hs.719702   20.51    3.578947368   73.40421053
  238846_at      TNFRSF11A     Hs.204044   11.24    6.416666667   72.12333333
  222911_s\_at   CXorf36       Hs.98321    18.06    3.953703704   71.40388889
  231887_s\_at   KIAA1274      Hs.202351   13.86    4.685185185   64.93666667
  202411_at      IFI27         Hs.532634   8.4      7.202764977   60.50322581
  205581_s\_at   NOS3          Hs.647092   11.89    4.958333333   58.95458333
  206481_s\_at   LDB2          Hs.714330   18.81    3.117505995   58.64028777
  224385_s\_at   MOV10L1       Hs.62880    5.37     10.09090909   54.18818182
  230250_at      PTPRB         Hs.434375   13.61    3.787878788   51.5530303
  230673_at      PKHD1L1       Hs.170128   4.04     12.625        51.005
  222908_at      FAM38B        Hs.585839   7.79     6.5           50.635
  240646_at      GIMAP8        Hs.647121   8.59     5.7           48.963
  231792_at      MYLK2         Hs.86092    13.89    3.5           48.615
  208983_s\_at   PECAM1        Hs.514412   9.63     4.606138107   44.35710997
  51158_at       FAM174B       Hs.27373    12.38    3.533333333   43.74266667
  214156_at      MYRIP         Hs.594535   3.08     12.88888889   39.69777778
  205507_at      ARHGEF15      Hs.443109   11.7     3.202898551   37.47391304
  218901_at      PLSCR4        Hs.477869   7.29     5.044217687   36.77234694
  228342_s\_at   ALPK3         Hs.459183   12.23    3             36.69
  219247_s\_at   ZDHHC14       Hs.187459   4.32     8.176470588   35.32235294
  213552_at      GLCE          Hs.183006   10.2     3.446428571   35.15357143
  205247_at      NOTCH4        Hs.436100   6.44     5.409090909   34.83454545
  205003_at      DOCK4         Hs.654652   11.06    3.085365854   34.12414634
  218711_s\_at   SDPR          Hs.26530    8.83     3.822222222   33.75022222
  201801_s\_at   SLC29A1       Hs.25450    10.62    3.057324841   32.46878981
  218995_s\_at   EDN1          Hs.511899   9.37     3.31779661    31.08775424
  206855_s\_at   HYAL2         Hs.76873    5.2      5.645502646   29.35661376
  226636_at      PLD1          Hs.382865   8.18     3.347826087   27.38521739
  211177_s\_at   TXNRD2        Hs.443430   6.85     3.825688073   26.2059633
  228245_s\_at   OVOS          Hs.524331   6.8      3.851485149   26.19009901
  218805_at      GIMAP5        Hs.647079   4.08     6.153846154   25.10769231
  233924_s\_at   EXOC6         Hs.655657   6.79     3.680672269   24.99176471
  223796_at      CNTNAP3       Hs.658328   7.27     3.396039604   24.68920792
  220945_x\_at   MANSC1        Hs.591145   8.04     3.065934066   24.65010989
  230800_at      ADCY4         Hs.443428   7.13     3.260869565   23.25
  237466_s\_at   HHIP          Hs.507991   5.84     3.927492447   22.93655589
  205635_at      KALRN         Hs.8004     4.8      4.657894737   22.35789474
  240890_at      LOC643733     Hs.713751   3.71     5.5           20.405
  213030_s\_at   PLXNA2        Hs.497626   5.18     3.504761905   18.15466667
  243337_at      FREM3         Hs.252714   3.42     4.461538462   15.25846154
  226882_x\_at   WDR4          Hs.248815   3.51     4.122807018   14.47105263
  232080_at      HECW2         Hs.654742   4.02     3.578947368   14.38736842
  210044_s\_at   LYL1          Hs.46446    4.42     3.239669421   14.31933884
  205680_at      MMP10         Hs.2258     4.03     3.326693227   13.40657371
  206222_at      TNFRSF10C     Hs.655801   3.29     3.714285714   12.22
  219777_at      GIMAP6        Hs.647105   3.64     3.335664336   12.14181818
  203650_at      PROCR         Hs.647450   3.27     3.582278481   11.71405063
  222446_s\_at   BACE2         Hs.529408   3.26     3.023094688   9.855288684
  238036_at      SHE           Hs.591481   3.06     3.219512195   9.851707317

![**Colorgram depicting the expression of EC-restricted genes in different cell types in the primary set**. The columns represent the samples and rows represent the genes. Gene expression is shown with a pseudocolor scale (-3 to 3) with red color denoting high expression level and green color denoting low expression level of the gene. The scatter plots along the heatmap depict the different patterns in expression of EC-restricted genes obtained using K mean clustering. The K mean clusters are represented as scatter plots with bars denoting the mean expression level. Pattern I and IV depict a range of expression patterns exhibited by EC-restricted genes. For example pattern IV and I denotes the genes that are highly expressed in all endothelial cell types (pan EC) and HMVEC cells respectively.](1471-2164-11-342-2){#F2}

![**Expression of ECs restricted genes in REFEXA database**. **A)**Hierarchical clustering analysis of EC-restricted expression genes using REFEXA gene expression data. The columns represent the samples (primary endothelial and non endothelial cells from REFEXA database) and rows represent the genes. The detailed information about the primary cells can be obtained from REFEXA database <http://157.82.78.238/refexa/main_search.jsp>. Gene expression is shown with pseudocolor scale (-3 to 3) with red denoting high expression level and green denoting low expression level of gene.](1471-2164-11-342-3){#F3}

![**Validation of a selected subset of endothelial-restricted genes by quantitative RT-PCR**. Validation of a subset of EC-restricted genes from Table 1 was conducted using primary ECs and non-ECs by quantitative RT-PCR (n = 3 per cell type). The gene symbol is listed for each gene. RQ refers to \"relative quantity\" where the expression in HUVECs has been set to 1.0 and the relative expression of the other cell types are compared to that in HUVECs.](1471-2164-11-342-4){#F4}

Pathways and Gene Ontology (GO) Processes modulated by EC-restricted genes
--------------------------------------------------------------------------

We performed an enrichment analysis of the EC-restricted genes to identify the pathways and GO processes where the EC-restricted genes occur more often than would be expected by random distribution. The pathway enrichment analysis was performed using the MetaCore tool of the GeneGO package where P values of \<0.05 (FDR adjusted) are considered significant. The enrichment analysis identified a set of statistically significant enriched pathways (Figure [5A](#F5){ref-type="fig"}). The most highly enriched pathways included \"*EC contacts by junctional/nonjuctional mechanisms*\", \"*Regulation of eNOS activity in cardiomyocytes and endothelial cells*\", \"*thrombospondin signaling*\", \"*Role of PKA in cytoskeleton reorganization*\", many of which would be expected based on the identified gene list. The enrichment analysis for GO categories was performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) program. The top clusters of biological processes and metabolic functions that are enriched in the set of differentially expressed genes are shown in Figure [5B](#F5){ref-type="fig"}. The most highly enriched clusters of the gene ontology categories included vasculature development and angiogenesis, immune responses, cell adhesion, and cell motility and migration. Vascular development and angiogenesis is the highest enriched GO cluster in which the EC-restricted genes are overrepresented (Enrichment score 4.72). This finding supports the overall concept that at least a subset of the genes we identified as being EC-restricted have previously been described in processes known to involve ECs.

![**Enrichment analysis of EC-restricted genes**. **A)**Top enriched Canonical Pathways **B)**Top enriched GO Processes. **C)**Top enriched disease set. The analysis for pathways and disease set enrichment was performed using the MetaCore tool of the GeneGo package. The GO categories enrichment analysis was performed using the DAVID tool. The Bar graphs depict the enriched pathway or Go process categories and -log of the P value. The P value depicts the significance of enrichment, the smaller is the P value the more significant is the enrichment. The pathways and disease sets with FDR adjusted P value \< 0.05 are considered significant. The panel for gene ontology enrichment depicts the enrichments for each GO category (-log P value) as well as the Escore for a cluster of related GO categories.](1471-2164-11-342-5){#F5}

### Disease set enrichment of EC-restricted genes

In order to evaluate whether the EC-restricted genes are potentially linked to the pathogenesis of certain human diseases, we performed a disease set enrichment analysis using disease sets on the basis of published literature (DSPL). DSPL enrichment analysis was performed using the MetaCore tool in the GeneGO package. The disease associations are summarized in Figure [5C](#F5){ref-type="fig"}, depicting the top diseases in which EC-restricted are enriched. The EC-restricted genes are enriched in the many cardiovascular diseases including ventricular dysfunction, myocardial infarction, hypertension, diabetic angiopathies, arteriosclerosis, and several other vascular diseases. Interestingly, ischemia was listed as a disease in which the EC-restricted are over-represented (P value = 2E-06). The EC-restricted genes are also enriched (P value \< 0.01) in neurological diseases including subarachnoid hemorrhage (P value = 3.00E-07).

Regulatory mechanism governing EC-restricted genes
--------------------------------------------------

To begin to understand the complex and intricate regulation of the EC-restricted genes, we were interested in determining whether certain transcription factors or miRNAs might be involved in regulating these genes. Transcription factors play a critical role in defining cell and tissue specificity of gene expression. In this study the TFactor enrichment analysis was performed on two sets of EC-restricted genes categorized on the basis of expression profiles; the sets of genes are highly expressed in i); all EC types (pan EC), ii); only in HMVEC. The TFactor enrichment analysis was only performed on these two sets as they constitute the major fraction of EC-restricted genes. TFactor enrichment analysis was performed using the ExPlain tool, a program for gene expression analysis from BIOBASE. We performed the analysis on a region 2 kb upstream to 100 bp downstream of each of the EC-restricted genes using vertebrate_non_redundant matrices (yes set). Background frequencies were calculated based on the promoters of human housekeeping genes (No set) \[[@B12]\]. A TF binding site was considered to be enriched in a gene set on the basis of the P value (P value \< 0.001 and Yes/No \> 1.2). The analysis identified binding sites for \>20 transcription factors, among the EC-restricted genes expressed in all EC, and in the subset enriched only in microvascular ECs \[Figure [6](#F6){ref-type="fig"}\]. Binding sites for the TF factor that were identified for both of these sets of genes included, CDXA, GATA, IPF1, NFAT, CDP, AIRE and OCT1. However, the binding sites for particular sets of transcription factors (e.g. FAC1, POU1F1, STAT1, AR, SRF, LRH) are only enriched in promoters of microvascular EC-restricted genes.

![**Regulation analysis of EC-restricted genes**. The list of the transcription factor binding sites that are enriched in 2 kb upstream to 100 bp downstream region. The enrichment in gene sets that are highly expressed in all endothelial cells and only microvascular EC is shown in black and grey color respectively. The X-axis represents the transcription factors and Y-axis represents -log P value.](1471-2164-11-342-6){#F6}

Another mechanism by which gene expression can be regulated is through small noncoding RNAs or microRNAs (miRNA). MiRNAs regulate gene expression through translational repression of mRNA by promoting the degradation of mRNA by binding to specific sequences in the untranslated regions of the mRNA. We performed a bioinformatics analysis of the EC-restricted genes in order to identify whether the identified EC-restricted genes are targets of miRNAs. We used *composite regulatory signature database*(CRSD) web tools that take into consideration the sequence match and free energy of binding to predict binding sites \[[@B16]\]. Our analysis identified 31 miRNA binding sites that are significantly enriched (P value \< 0.05) in the UTR of the EC-restricted genes \[Figure [7](#F7){ref-type="fig"}\]. Mir-432, Mir-188, and Mir-331 target each have putative binding sites in the 3\' UTR of \>8 EC-restricted genes. A summary of the miRNA binding sites for EC-restricted genes is provided in Table [2](#T2){ref-type="table"}. Additionally details of miRNA Binding sites along with target and reference sequences are provided in Additional File [2](#S2){ref-type="supplementary-material"}.

###### 

List of significantly enriched miRNAs binding sites.

  microRNA         Hits   P-Value    FDR           **Gene Symbol**,
  ---------------- ------ ---------- ------------- -------------------------------------------------------------------------
  hsa-miR-432\*    11     1.53E-04   0.035458796   PALMD,RAPGEF5,LOC90139,MYLK2, CETP,TIE1,GLCE,VWF,ROBO4,KIAA1274, PDE2A,
                                                   
  hsa-miR-188      10     7.60E-04   0.058786382   CDH5,EGFL7,CXorf36,,RNASE1,SEMA6B, ESAM,RGS3,ROBO4,HYAL2,
                                                   
  hsa-miR-132      6      6.39E-04   0.074133993   IL1RL1,CXorf36,LOC90139,SLC29A1, IPO11,LOC116441,
                                                   
  hsa-miR-331      9      0.002161   0.10028083    TXNRD2,LOC90139,FLJ22746,BCL6B, SEMA6B,ESAM,KIAA1274,TBX1,ICAM2,
                                                   
  hsa-miR-296      9      0.001918   0.111262412   ARHGEF15,CDH5,APLN,RNASE1, SEMA6B,ESAM,ROBO4,CGNL1,
                                                   
  hsa-miR-512-5p   8      0.00932    0.166330341   APLN,RAPGEF5,BCL6B,SLCO2A1, LOC400451,KDR,ROBO4,FLJ46061,
                                                   
  hsa-miR-503      8      0.008909   0.172244646   APLN,LOC90139,ESAM,MGC20262, VWF,ROBO4,ZDHHC14,HYAL2,
                                                   
  hsa-miR-518e     5      0.008905   0.187818163   LAMP3,NOTCH4,BCL6B,GLCE,SEMA6B,
                                                   
  hsa-miR-520a\*   8      0.008722   0.202353355   EGFL7,FLJ10241,APLN,ABCA4, HSD17B2,SHANK3,ESAM,CGNL1,
                                                   
  hsa-miR-345      8      0.008564   0.220764545   FLJ10241,RAPGEF5,MYLK2,ADCY4, PLSCR4,GJA4,RGS3,PDE2A,
                                                   
  hsa-miR-490      8      0.008331   0.241605345   CDH5,ESAM,MGC20262,ROBO4, FLJ46061,MOV10L1,CGNL1,ICAM2,
                                                   
  hsa-miR-299-3p   5      0.007968   0.264095479   APLN,TNFRSF11A,TIE1, PECAM1,ROBO4,
                                                   
  hsa-miR-328      8      0.007307   0.282532121   EGFL7,CLDN5,CXorf36,LOC90139,SEMA6B, RGS3,ROBO4,KIAA1274,
                                                   
  hsa-miR-525      7      0.029061   0.293137643   EGFL7,FLJ10241,RAPGEF5,NOTCH4, FLJ22746,ESAM,FLJ46061,
                                                   
  hsa-miR-337      7      0.027316   0.301772827   RAPGEF5,FLJ22746,SHANK3, LOC400451,PLSCR4,KIAA1274,

The miRNAs that are expressed at relatively low level as compared to miRNA from opposite/guided standard are marked with star (\*).

![**Regulation analysis of EC-restricted genes in term of MiRNA targets**. The list of the miRNA that are enriched in 3\' UTR of EC specific genes. The X-axis represents the miRNA\'s and Y-axis represents -log P value. The miRNAs from the opposite standard of guided RNA strand are marked with star (\*).](1471-2164-11-342-7){#F7}

Expression pattern of EC-restricted genes in tissues
----------------------------------------------------

A better understanding of how the EC-restricted genes are expressed in different tissues can help to define their function and potential use as disease biomarkers. Relative expression of the EC-restricted genes in several normal tissues was obtained using the Source databases <http://source.stanford.edu>. In the source database the normalized gene expression represents the relative expression level of a gene in different tissues. The colorogram depicting the percentage of relative expression of each gene is shown in Figure [8](#F8){ref-type="fig"}. The analysis demonstrates that most of the endothelial restricted genes have preferential expression in vascular tissues. In particular MMRN1, BMX, ANGPT2 and CDH5 demonstrate high expression levels in vascular tissues. VWF, TIE1, ROBO4 and ECSCR have very high expression levels in umbilical cord tissue (Table [3](#T3){ref-type="table"}). These results strengthen our finding that these genes have relatively high expression levels in vascular related tissues.

###### 

Normalized Expression Level of top endothelial restricted genes obtained from the Source database.

  ------------------------------------------------------
  Gene Symbol   Rank Score    Normalized Expression
  ------------- ------------- --------------------------
  MMRN1         11157.50625   Vascular (29.44%)\
                              Umbilical cord (16.7%)

                              

  CLDN5         5933.421875   Adipose (66.3%)

                              

  VWF           4772.862931   Umbilical cord (43.9%)

                              

  BMX           4447.913846   Vascular (56.1%),\
                              Umbilical cord (10.1%),\
                              Ganglia (11.8%)

                              

  ANGPT2        1412.88625    Vascular (19.2%),\
                              Umbilical cord (16.3%),\
                              Placenta (12.5%)

                              

  GJA4          1284.435      Adipose (24.4%),\
                              Placenta (10.8%),\
                              Ganglia (9.3%)

                              

  CDH5          1115.751864   Vascular (19.6%),\
                              Placenta (29.4%)

                              

  TIE1          1107.308411   Umbilical cord (16.0%),\
                              Ganglia (22.2%)

                              

  ROBO4         975.358913    Umbilical cord (82.4%)

                              

  ECSCR         646.6127586   Umbilical cord (44.6%)
  ------------------------------------------------------

The relative expression level of the genes in different tissues is expression as percentage. The gene expression data for generating the normalized expression level was DbEST database of normal tissues at NCBI.

![**Relative normalized expression levels of EC-restricted genes in normal tissues**. The expression level is expressed as relative percentage of expression in different tissues with red, yellow and green color denoting higher, median and lower expression levels respectively. The rows represent each gene and columns represent each normal tissue type.](1471-2164-11-342-8){#F8}

To further explore whether any of the EC-restricted genes have specific expression in particular tissues, we obtained the immunohistochemistry data for 61 out of the 109 EC-restricted genes. The majority of the EC-restricted genes demonstrate a ubiquitous expression in different normal tissues (Additional File [3](#S3){ref-type="supplementary-material"}). A small subset of the genes show a restricted expression pattern in normal tissues. For example, VWF and ICAM2 are enriched in soft tissues. BMX, one of the top ranked endothelial restricted genes has preferential expression in the epididymis. CLDN5 is preferentially expressed in glandular cells of various body tissues. Interestingly, about 85% of genes depict moderate to high levels of expression in soft tissues.

Discussion
==========

The results of our study demonstrate that of over 43,000 transcripts evaluated, only 152 appear to be highly restricted to the endothelium. Several of the genes identified have previously been reported to exhibit an EC-restricted expression pattern and have known functions in ECs. Examples of these genes include angiopoietin-2, von Willebrand\'s Factor (vWF), EC nitric oxide synthase (eNOS), and Pecam-1 (CD31). The pathways, and GO categories of the identified genes support a role for these genes in vascular development, angiogenesis, and EC function.

Although several of the EC-restricted genes have previously been shown to contribute to the regulation of normal EC function, many others have not been characterized as having a particular role in EC. The genes identified as being EC-restricted fall into several categories, including proteins involved in transcriptional regulation, cell adhesion, signal transduction, and intracellular trafficking. The determination that these genes are enriched in ECs may lead to future studies that define their specific role in regulating EC function.

The endothelium is known to play an important role in a number of human diseases, and so it was not a surprise that alterations in the expression of these genes are associated with a number of cardiovascular disorders. Mutations or alterations in the expression of several of the genes listed have been shown to be associated with the development of hypertension. For example, mutations in the eNOS gene have been linked to patients with essential hypertension \[[@B21]-[@B23]\]. Similar associations have been observed with mutations in the endothelin-1 gene \[[@B24],[@B25]\]. More recent studies point toward a link between obesity and hypertension. There has been particular interest at understanding the role of adipocytokines and their receptors in the development of hypertension. Previous studies have suggested a causal link between leptin levels in obese patients and the development of hypertension \[[@B26]\]. A more recently discovered adipocytokine, apelin, is predominantly expressed in the ECs of the heart and support a role for apelin in the development of hypertension and cardiac hypertrophy \[[@B27]\].

The endothelium is known to play an important paracrine role with respect to cardiac function and development. The TGFbeta family member cytokine, bone morphogenetic protein-4 (BMP-4), is known to play an important role during cardiac development \[[@B28]\]. Increased expression of BMP-4 may similarly be reflective of a state of EC dysfunction. Exposure of ECs to BMP-4 promotes ROS generation \[[@B29]\]. BMP-4 expression is increased in EC exposed to abnormal or unstable flow, compared to regions of laminar shear flow \[[@B30]\]. Venous and microvessel ECs exposed to BMP-4 rapidly undergo apoptosis \[[@B31]\]. These results suggest the possibility that BMP-4 could be a possible therapeutic target in the setting of heart failure to improve or reverse EC dysfunction.

The functional and structural integrity of the central nervous system depends on tightly controlled coupling between neural activity and cerebral blood flow. This requires the close interaction of neuronal cells and vascular cells in a complex that is known as the neurovascular unit. Recent experimental evidence suggest that dysfunction of the neurovascular unit may be an early event in Alzheimer\'s disease. Studies in transgenic mice overexpressing the amyloid precursor protein (APP) exhibit abnormalities in blood flow in response to functional hyperemia prior to the development of amyloid plaques or vascular amyloid \[[@B32]\]. Administration of soluble amyloid beta protein results in vasoconstriction, EC dysfunction and a reduction in CBF. One of the main mechanisms by which EC dysfunction occurs is through inactivation or reduced function of EC nitric oxide synthase (eNOS). Amyloid beta also induces the production of reactive oxygen species, alteration in the expression of tight junction proteins, and an increased rate of EC apoptosis \[[@B33]\]. In the brain tissue samples of patients with AD, we observed a significant increase in the expression of selected adherens and tight junction proteins including VE-cadherin, claudin-5, and connexin 37 (GJA4). Systemic administration of the amyloid beta peptide 1-42 to rats is associated with alterations in the expression and cellular localization of several tight junction proteins \[[@B33]\]. Another EC-restricted gene found to be significantly upregulated in the AD brain tissue samples is von Willebrand\'s Factor (vWF). Increased levels of vWF promote blood clotting. Increased vWF has been found in heme-rich deposits (HRDs) in patients with dementia \[[@B34]\]. HRDs are also rich in fibrinogen, collagen IV, and red blood cells, and are thought to be the residua of capillary bleeds, or microhemorrhages. In patients with acute ischemic stroke and vascular dementia, vWF levels have also been shown to be increased \[[@B35]\].

Our analysis of potential transcription factors that might be involved in regulating the expression of the identified EC-restricted genes, based on conserved binding sites in the regulatory regions of these genes led to the identification of several classes of transcription factors. Most of these transcription factors have not previously been described as playing a major role in the regulation of EC-restricted genes with some exceptions. Members of the ETS and GATA transcription factor families have been shown to regulate a number of endothelial genes including vWF, VE-cadherin, and Tie1 \[[@B36]-[@B38]\]. Interestingly, several conserved binding sites were identified only in the regulatory regions of the microvascular ECs suggesting that members of these transcription factor families may play a unique role in determining endothelial gene expression in microvessels.

Over the past several years a role for microRNAs has been demonstrated to play a role in regulating EC gene expression, function, and in the process of angiogenesis. Although most of the miRNAs we identified have not been described for their roles in regulating EC-restricted genes, a few have. For example, hsa-miR-296 has recently been shown to play a regulatory role in angiogenesis (39). Angiogenic factors can increase the expression of hsa-miR-296. Down regulation of hsa-miR-296 in ECs inhibits angiogenic responses in cultured ECs. Furthermore, inhibition of hsa-miR-296 with antagomirs reduced angiogenesis in tumor xenografts in vivo. Similarly, hsa-miR-328 has been implicated in the regulation of CD44 \[[@B39]\]. CD44 regulates a wide variety or processes including angiogenesis and inflammation. The fact that only a small subset of the more than 700 microRNAs has thus far been shown to regulate EC-restricted genes or play a role in regulating EC function suggests that several additional members, including those we have identified, may well also play a role in regulating the expression of selected EC-restricted genes or EC function.

We recognize that there are potential limitations of our study. First, the study used expression-profiling data based on RNA obtained from human tissues or cells. Although several of the genes identified are known to be vascular-specific, the newly identified genes will ultimately need further validation as to the true extent of their EC specificity, at the level of protein and/or RNA both in cells and tissues, and to validate their EC-restricted pattern within the identified tissues.

Conclusion
==========

Our study validates the existence of a finite number of endothelial-restricted genes most of which are ubiquitously expressed. Several of these are restricted to cells of microvascular origin. Although several of the genes are known to play important roles in endothelial function, the exact functional role of many others in endothelial cells remains to be defined. We hope that our study provides an initial catalogue of EC-restricted genes that can lead to further studies that either link alterations in the expression of these genes to a variety of human diseases via their role as biomarkers or are ultimately shown to play a causal role in the pathogenesis of the particular human diseases.

Authors\' contributions
=======================

MB contributed to the overall experimental design, bioinformatics analysis and writing of manuscript. LY contributed in cell culture and RNA extraction. DBK contributed in isolation of B cell and T cells from donors Blood. HHO contributed in statistical analysis. TAL contributed in analysis of result and writing of manuscript. PO contributed to the overall design of the experiments and writing of the manuscript. All authors have read and approved the final manuscript.

Supplementary Material
======================

###### Additional file 1

**Nucleotide sequence of primers used for RT-PCR to validate expression pattern of selected EC-restricted genes**.

###### 

Click here for file

###### Additional file 2

**Summary of miRNA Binding sites along with target and reference sequences**.

###### 

Click here for file

###### Additional file 3

**Immunohistochemistry based expression level of genes in different tissues**. Rows represent the different tissues and columns represent the different EC-restricted genes. The expression level is shown in four color circle scheme i) Red represents strong expression ii) Orange represents moderate expression, iii) Yellow represents weak expression, iv) White represents no detectable expression and Black represents no representative images. The data was obtained from human protein atlas database.
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